AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03850691
Drug: Nivolumab: Cohort 2 (Ocular)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study
Trial: NCT03457844
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Trial: NCT03690362
Drug: VNRX-5133 and VNRX-5022
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion
Trial: NCT00004176
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004176
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004176
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02102594
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
Trial: NCT00937092
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
Trial: NCT02232555
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02148016
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02148016
Drug: Betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02148016
Drug: Limbal stem cells (LSCs)
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogeneic ABCB5-positive limbal stem cells (DB18349)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00678964
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg, p.o., once daily
Trial: NCT00678964
Drug: Vinorelbine and Carboplatin
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
Trial: NCT00481013
Drug: Valproic Acid (VPA)
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Valproic Acid and Levocarnitine; capsules
Trial: NCT00516490
Drug: triptorelin acetate
RxNorm normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
Trial: NCT01075464
Drug: MEGF0444A
RxNorm normalized name: MEGF0444A
DrugBank: Parsatuzumab (DB14897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous escalating dose
Trial: NCT01075464
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT01075464
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT04202536
Drug: Besifovir Dipivoxil Maleate
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Besifovir dipivoxil (DB05020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Besifovir 150 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d. Other Name: Besifovir®
Trial: NCT03473743
Drug: Erdafitinib
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive erdafitinib orally.
Trial: NCT03473743
Drug: Cetrelimab
RxNorm normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive cetrelimab by intravenous infusion.
Trial: NCT03473743
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive cisplatin by intravenous infusion as a part of platinum chemotherapy.
Trial: NCT03473743
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive carboplatin by intravenous infusion as a part of platinum chemotherapy.
Trial: NCT02521285
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04202536
Drug: Tenofovir disoproxil fumarate(TDF)
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg tablet administered orally once daily Other Name: VIREAD®
Trial: NCT00934232
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
Trial: NCT00095459
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01390428
Drug: Grazoprevir
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
Trial: NCT00003328
Drug: porfiromycin
RxNorm normalized name: Porfiromycin
DrugBank: Porfiromycin (DB06478)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01556997
Drug: XOMA 985
RxNorm normalized name: XomaZyme 791
DrugBank: XomaZyme-791 (DB17216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PERa/AMLb capsule taken once daily by mouth for six weeks
Trial: NCT01556997
Drug: Amlodipine Besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMLb capsule taken once daily by mouth for six weeks
Trial: NCT01556997
Drug: Perindopril Erbumine
RxNorm normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PERe capsule taken once daily by mouth for six weeks
Trial: NCT03726736
Drug: Anlotinib combined Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
Trial: NCT03726736
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
Trial: NCT02445859
Drug: Cefuroxime 4 hourly bolus
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
Trial: NCT02826252
Drug: Iloprost,(Ventavis, BAYQ6256)
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
Trial: NCT04118777
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
Trial: NCT00284154
Drug: Vinflunine
RxNorm normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320mg/m2 every 21 days as a 15-20 minute infusion
Trial: NCT02039323
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02039323
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04212832
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 ml/kg %0.25 bupivacaine
Trial: NCT01048684
Drug: Mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variation of mannitol dose
Trial: NCT03358706
Drug: Ustekinumab IV Infusion
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.
Trial: NCT03358706
Drug: Ustekinumab SC Injection
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.
Trial: NCT02425202
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-operative continuous infusion until 0600 the next day
Trial: NCT03358706
Drug: Midazolam 2 mg
RxNorm normalized name: midazolam 2 MG/ML
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.
Trial: NCT00702520
Drug: Corifollitropin alpha (MK-8962, Org 36286) 100 ug
RxNorm normalized name: tocopherol,DL-alpha 100 UNT
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
Trial: NCT00702520
Drug: Corifollitropin alpha (MK-8962, Org 36286) 150 ug
RxNorm normalized name: alpha-D-galactosidase enzyme 150 UNT
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
Trial: NCT00752869
Drug: dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg by mouth one time per day for 1 year
Trial: NCT00856843
Drug: Polyethylene glycol 3350 based bowel preparation
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for oral administration prior to colonoscopy
Trial: NCT03358706
Drug: Warfarin 10 mg
RxNorm normalized name: warfarin 10 mg oral tablet
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.
Trial: NCT03358706
Drug: Vitamin K 10 mg
RxNorm normalized name: vitamin K 10 MG
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
Trial: NCT00702520
Drug: Triptorelin
RxNorm normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
Trial: NCT02035553
Drug: Pimavanserin tartrate
RxNorm normalized name: Pimavanserin tartrate
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
Trial: NCT00509899
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
Trial: NCT03019991
Drug: Danoprevir
RxNorm normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
Trial: NCT03019991
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
Trial: NCT03358706
Drug: Omeprazole 20 mg
RxNorm normalized name: omeprazole 20 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.
Trial: NCT03358706
Drug: Dextromethorphan 30 mg
RxNorm normalized name: dextromethorphan 30 mg oral capsule
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.
Trial: NCT01680653
Drug: Mini-glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mini dose glucagon given for glucose \<70 mg/dl at a dose of 1unit/year of age
Trial: NCT01854697
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT01854697
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01854697
Drug: Pegylated Interferon alpha 2-a (PegIFN)
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-filled syringe
Trial: NCT01014247
Drug: Avelox (Moxifloxacin, BAY12-8039)
RxNorm normalized name: moxifloxacin Injection [Avelox]
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg
Trial: NCT02335255
Drug: Naftifine Hydrochloride Gel 2%
DrugBank: Naftifine (DB00735)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
Trial: NCT02946892
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol will be given for 12 weeks and then an exercise test will be performed
Trial: NCT01457417
Drug: DKN-01
RxNorm normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
Trial: NCT03646968
Drug: Anlotinib and Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)
Trial: NCT02893111
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
Trial: NCT00199576
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00829829
Drug: Rilonacept 80 mg
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
Trial: NCT00829829
Drug: Rilonacept 160 mg
RxNorm normalized name: RILONACEPT 160 mg in 2 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Arcalyst]
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
Trial: NCT00001863
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03257241
Drug: A arm (DA-90)
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is \> 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
Trial: NCT03257241
Drug: A arm (CLAG-M)
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol.
Trial: NCT04580537
Drug: Enstilar
RxNorm normalized name: Enstilar
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily application on affected fingers (nail plates, nail folds, and surrounding skin)
Trial: NCT00618709
Drug: ATX-101
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATX-101 single dose
Trial: NCT02342977
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will randomly receive lacosamide
Trial: NCT01078298
Drug: varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
Trial: NCT04451668
Drug: FT218
RxNorm normalized name: Solriamfetol
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: once nightly sodium oxybate extended release
Trial: NCT03715387
Drug: Tacrolimus Topical 0.1% Topical Ointment
RxNorm normalized name: tacrolimus topical 0.1% topical ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus ointment
Trial: NCT03715387
Drug: Polysporin Ointment
RxNorm normalized name: Polysporin Ointment
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysporin ointment
Trial: NCT00866333
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entinostat tablets
Trial: NCT02314754
Drug: Mifepristone followed by misoprostol 24-48 hours later
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
Trial: NCT03631654
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
Trial: NCT03348098
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg, po, qd. 12weeks
Trial: NCT03348098
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
Trial: NCT01653327
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
Trial: NCT00659776
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2\* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)